Hematologic Oncology | Specialty

Brexucabtagene Autoleucel Safe, Efficacious as Therapy for Pediatric B-Cell ALL in ZUMA-4

June 13th 2021

Axi-Cel Induces Superior Responses, Survival in Relapsed/Refractory Follicular Lymphoma

June 12th 2021

Compared to currently available therapies, treatment with axicabtagene ciloleucel induced substantial objective response rate, progression-free survival, time to next treatment and overall survival improvements in patients with relapsed/refractory follicular lymphoma.

Rusfertide Eliminates Need for Phlebotomy, Reverses Iron Deficiency in Polycythemia Vera

June 12th 2021

Rusfertide has been shown to be an effective option for patients with polycythemia vera in that it reverses iron deficiency, improves disease-related symptoms, and eliminates the need for therapeutic phlebotomy.

Luspatercept Achieves Impressive Hemoglobin Increase in Non-Transfusion–Dependent Beta-Thalassemia

June 11th 2021

Luspatercept-aamt achieved a 77.1% mean hemoglobin increase of 1.0 g/dL or higher from baseline over a continuous 12-week interval during weeks 13 to 24 in the absence of red blood cell transfusions vs 0% with placebo in patients with non-transfusion–dependent β-thalassemia.

Dr. Wang on the Potential Impact of Menin Inhibitors in AML

June 11th 2021

Eunice Wang, MD, discusses the potential impact of menin inhibitors on the treatment of acute myeloid leukemia.

Dr. Shah on Results Seen With Brexucabtagene Autoleucel in Relapsed/Refractory B-ALL

June 11th 2021

Bijal Shah, MD, MS, discusses the results seen with brexucabtagne autoleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia, as demonstrated in the phase 2 ZUMA-3 trial.

Zandelisib/Zanubrutinib Yields Promising Responses in R/R CLL, and B-cell Malignancies

June 11th 2021

A 60 mg dose of zandelisib administered on an intermittent schedule from cycle 1 plus 80 mg of zanubrutinib twice daily yielded promising response rates in patients with relapsed/refractory B-cell malignancies and chronic lymphocytic leukemia.

Shah Spotlights the Potential Benefit of Brexucabtagene Autoleucel in Relapsed/Refractory B-Cell ALL, and Beyond

June 11th 2021

Bijal Shah, MD, MS, discusses the key findings of the ZUMA-3 trial, as well as key safety information regarding brexucabtagene autoleucel as a treatment for patients with heavily pretreated patients with relapsed/refractory B-cell ALL.

ALLO-501A With ALLO-647 Lymphodepletion Shows Early Efficacy in Relapsed/Refractory Large B-Cell Lymphoma

June 11th 2021

Treatment with the allogeneic CAR T-cell product ALLO-501A elicited encouraging signals of clinical activity when used with ALLO-647 lymphodepletion in patients with relapsed/refractory large B-cell lymphoma who did not previously receive autologous CAR T-cell therapy.

Allo-Transplant Recommended for Eligible Patients With Myelofibrosis

June 10th 2021

Allogeneic hematopoietic cell transplant should be considered a standard of care option for patients with high-risk myelofibrosis, according to findings from a systematic review and meta-analysis.